Synthesis and Anti-Trypanosoma cruzi Biological Evaluation of Novel 2-Nitropyrrole Derivatives - Archive ouverte HAL Access content directly
Journal Articles Molecules Year : 2022

Synthesis and Anti-Trypanosoma cruzi Biological Evaluation of Novel 2-Nitropyrrole Derivatives

(1, 2) , (1, 2) , (1, 2) , (1, 2) , (1, 3) , (1, 2)
1
2
3

Abstract

Human American trypanosomiasis, called Chagas disease, caused by T. cruzi protozoan infection, represents a major public health problem, with about 7000 annual deaths in Latin America. As part of the search for new and safe anti-Trypanosoma cruzi derivatives involving nitroheterocycles, we report herein the synthesis of ten 1-substituted 2-nitropyrrole compounds and their biological evaluation. After an optimization phase, a convergent synthesis methodology was used to obtain these new final compounds in two steps from the 2-nitropyrrole starting product. All the designed derivatives follow Lipinski’s rule of five. The cytotoxicity evaluation on CHO cells showed no significant cytotoxicity, except for compound 3 (CC50 = 24.3 µM). Compound 18 appeared to show activity against T. cruzi intracellular amastigotes form (EC50 = 3.6 ± 1.8 µM) and good selectivity over the vero host cells. Unfortunately, this compound 18 showed an insufficient maximum effect compared to the reference drug (nifurtimox). Whether longer duration treatments may eliminate all parasites remains to be explored.
Fichier principal
Vignette du fichier
Synthesis and Anti-Trypanosoma -molecules-27-02163-v2.pdf (4.66 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-03818628 , version 1 (18-10-2022)

Licence

Attribution - CC BY 4.0

Identifiers

Cite

Fanny Mathias, Youssef Kabri, Damien Brun, Nicolas Primas, Carole Di Giorgio, et al.. Synthesis and Anti-Trypanosoma cruzi Biological Evaluation of Novel 2-Nitropyrrole Derivatives. Molecules, 2022, 27 (7), pp.2163. ⟨10.3390/molecules27072163⟩. ⟨hal-03818628⟩
49 View
3 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More